RxDoctor Payments Data

Grace Tassa, MD

Family Medicine · Beverly Hills, CANPI 1689012908

Payments from drug & device makers

$743in general payments, 2019–2025

Across 31 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$252
  • Novo Nordisk$147
  • Gilead$124
  • AbbVie$57
  • Vanda Pharmaceuticals Inc.$50
  • Lilly USA, LLC$44
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$743100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen8$252
Novo Nordisk10$147
Gilead1$124
AbbVie3$57
Vanda Pharmaceuticals Inc.3$50
Lilly USA, LLC2$44
GSK1$21
Metuchen Pharmaceuticals1$21
Shire North American Group Inc1$17
Endo Pharmaceuticals Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$743 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$92,417
Medicare patients
145
Services billed
2,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$41,722
OzempicSemaglutide26$35,822
MounjaroTirzepatide13$13,881
SynthroidLevothyroxine Sodium39$4,132
Alendronate Sodium25$2,834
Levothyroxine Sodium105$1,577
Methenamine Hippurate15$1,382
Rosuvastatin Calcium133$1,378
Atorvastatin Calcium78$814
Metoprolol Succinate41$773
Olmesartan Medoxomil22$755
Estradiol11$610
Zolpidem Tartrate ErZolpidem Tartrate11$587
Metformin Hcl ErMetformin Hcl45$497
Fluticasone Propionate39$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$35,82226 claims
Lilly USA, LLCMounjaro$44$13,88113 claims
AbbVieSynthroid$57$4,13239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →